0001809519FALSE2701 Olympic BoulevardSanta MonicaCalifornia00018095192024-06-062024-06-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________
FORM 8-K
________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 6, 2024
________________________________________
GoodRx Holdings, Inc.
(Exact Name of Registrant as Specified in its Charter)
________________________________________
Delaware
001-39549
47-5104396
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
2701 Olympic Boulevard
Santa Monica, California
90404
(Address of Principal Executive
Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (855) 268-2822
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per
share
GDRX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders
On June 6, 2024, GoodRx Holdings, Inc. (the “Company”) held its Annual Meeting of Stockholders. Holders of the
Company’s Class A common stock were entitled to one vote per share held as of the close of business on April 8, 2024 (the
“Record Date”) and holders of the Company’s Class B common stock were entitled to ten votes per share held as of the
Record Date. A total of 79,472,296 shares of the Company’s Class A common stock and 278,619,320 shares of the
Company’s Class B common stock were present in person or represented by proxy at the meeting, representing
approximately 98.7% of the combined voting power of the Company’s Class A and Class B common stock as of the Record
Date. The following are the final voting results for the proposals considered and voted upon at the meeting, each of which
were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April
25, 2024.
Item 1 — Election of three Class I directors for a term of office expiring on the date of the Annual Meeting of Stockholders to
be held in 2027 and until their respective successors have been duly elected and qualified or until their respective earlier
death, resignation or removal.
Votes FOR
Votes WITHHELD
Broker Non-Votes
Douglas Hirsch
2,818,730,487
9,200,943
37,734,066
Kelly J. Kennedy
2,827,444,912
486,518
37,734,066
Agnes Rey-Giraud
2,818,445,912
9,485,518
37,734,066
Item 2 — Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public
accounting firm for the fiscal year ending December 31, 2024.
Votes FOR
Votes AGAINST
Votes ABSTAINED
Broker Non-Votes
2,865,260,377
336,904
68,215
0
Item 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.
Votes FOR
Votes AGAINST
Votes ABSTAINED
Broker Non-Votes
2,823,670,920
4,151,594
108,916
37,734,066
Based on the foregoing votes, the Company’s stockholders (i) elected Douglas Hirsch, Kelly J. Kennedy and Agnes Rey-
Giraud as Class I directors; (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent
registered public accounting firm for the fiscal year ending December 31, 2024; and (iii) approved, on an advisory (non-
binding) basis, the compensation of the Company’s named executive officers.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
GOODRX HOLDINGS, INC.
Date:
June 7, 2024
By:
/s/ Karsten Voermann
Name: Karsten Voermann
Title: Chief Financial Officer
v3.24.1.1.u2
Document And Entity Information
Jun. 06, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 06, 2024
Entity Registrant Name GoodRx Holdings, Inc.
Entity Emerging Growth Company false
Entity File Number 001-39549
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-5104396
City Area Code 855
Local Phone Number 268-2822
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $0.0001 par value per share
Trading Symbol GDRX
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001809519
Entity Address, Address Line One 2701 Olympic Boulevard
Entity Address, City or Town Santa Monica
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90404
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more GoodRx Charts.
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more GoodRx Charts.